Format

Send to

Choose Destination
See comment in PubMed Commons below
Arch Ophthalmol. 2007 Jun;125(6):751-6.

Anti-vascular endothelial growth factor bevacizumab (avastin) for radiation retinopathy.

Author information

1
The New York Eye Cancer Center, 115 E 61st St, New York, NY 10021, USA. pfinger@eyecancer.com

Abstract

OBJECTIVE:

To evaluate intravitreal bevacizumab for radiation retinopathy.

METHODS:

After plaque radiation therapy, 6 patients developed radiation retinopathy (retinal edema, hemorrhages, microangiopathy, and neovascularization). Intravitreal bevacizumab (1.25 mg in 0.05 mL) was periodically injected (every 6-8 weeks). Ophthalmic evaluations included visual acuity, ophthalmic examination, fundus photography, fluorescein angiography, and optical coherence tomography/scanning laser ophthalmoscopy (OCT/SLO) imaging.

RESULTS:

No bevacizumab-related ocular or systemic adverse effects have occurred within the first 8 months of therapy. Progressive reductions in retinal hemorrhages, exudates, cotton-wool spots, and microangiopathy were documented by photography, angiography, and OCT/SLO imaging. Decreased macular edema was the most common finding. Improvement or stabilization of visual acuity was noted in all cases.

CONCLUSIONS:

Intravitreal bevacizumab was tolerated, improved or maintained vision, and reduced hemorrhage and retinal edema (angiographic leakage). This study should lead to additional and longer-term studies of humanized monoclonal anti-vascular endothelial growth factor antibody therapy for radiation retinopathy.

PMID:
17562985
DOI:
10.1001/archopht.125.6.751
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center